Leptin replacement therapy with human recombinant leptin metreleptin has been shown to be an effective therapy to alleviate the metabolic complications associated with lipodystrophy, and has been approved by the FDA for the treatment of generalized lipodystrophy<unk> s. In Europe based on EMA, metreleptin should be used in addition to diet to treat lipodystrophy, where patients have loss of fatty tissue under the skin and build-up of fat elsewhere in the body such as in the liver and muscles. The medicine is used in: adults and children above the age of two years with generalised lipodystrophy (Berardinelli-Seip<unk>  and Lawrence<unk>  and in adults and children above the age of 12 years with partial lipodystrophy (including Barraquer-Simons<unk> , when standard treatments have failed. Volanesorsen is an Apo-CIII inhibitor that is currently being investigated as a potential therapeutic to reduce hypertriglycerides in Familial Partial Lipodystrophy patients in the BROADEN study.
symptom of Cushing's syndrome
symptom of Klinefelter syndrome
symptom of Graves' disease
symptom of Hashimoto's thyroiditis
symptom of Hypothyroidism
symptom of Kallmann syndrome
symptom of Type 1 diabetes
symptom of Pheochromocytoma